In peripheral blood, a gene signature of 15 differentially expressed genes, which includes MYC and CDK2, is predictive and prognostic to anti-CTLA4 immunotherapy treatment and 1 year overall survival in melanoma patients [88]. The gene discussed is CTLA4; the disease is melanoma.